This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading ...

For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without ...

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, ...

The world's first gene-edited horses in Argentina are making waves in polo, showcasing advances in CRISPR technology.

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

Argentina, widely regarded as the global capital of polo, has welcomed cloning and other breeding innovations. But CRISPR is different – for now.

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of CRSP stock now.

CRISPR-based therapeutics present market opportunities in infectious diseases through genome disruption, host gene editing, and immune cell engineering. Key areas include innovative products, emerging ...

Scientists have achieved the first DNA-free CRISPR gene editing in raspberries, reaching 19% efficiency and opening the door to faster breeding of firmer, more resilient berries — though regenerating ...

CRISPR editing augmented both innate and CAR-mediated NK cell function, leading to improved metabolic fitness and increased ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell. After that ...